Consistent with the predominant contribution of LAT1 in supplying cancer cells with essential amino acids, including leucine, treatment with NANV reduces mTORC1 activity in cancer cells [21–24, 26, 27, 29–31, 33]. The gene discussed is SLC7A5; the disease is cancer.